128 related articles for article (PubMed ID: 21498633)
1. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
2. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.
Mandriota SJ; Valentijn LJ; Lesne L; Betts DR; Marino D; Boudal-Khoshbeen M; London WB; Rougemont AL; Attiyeh EF; Maris JM; Hogarty MD; Koster J; Molenaar JJ; Versteeg R; Ansari M; Gumy-Pause F
Oncotarget; 2015 Jul; 6(21):18558-76. PubMed ID: 26053094
[TBL] [Abstract][Full Text] [Related]
3. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.
Powers JT; Tsanov KM; Pearson DS; Roels F; Spina CS; Ebright R; Seligson M; de Soysa Y; Cahan P; Theißen J; Tu HC; Han A; Kurek KC; LaPier GS; Osborne JK; Ross SJ; Cesana M; Collins JJ; Berthold F; Daley GQ
Nature; 2016 Jul; 535(7611):246-51. PubMed ID: 27383785
[TBL] [Abstract][Full Text] [Related]
4. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.
Gualdrini F; Corvetta D; Cantilena S; Chayka O; Tanno B; Raschellà G; Sala A
Oncotarget; 2010 Aug; 1(4):278-288. PubMed ID: 21304178
[TBL] [Abstract][Full Text] [Related]
5. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
6. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract][Full Text] [Related]
7. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
[No Abstract] [Full Text] [Related]
8. SESN1 functions as a new tumor suppressor gene via Toll-like receptor signaling pathway in neuroblastoma.
Hua Z; Chen B; Gong B; Lin M; Ma Y; Li Z
CNS Neurosci Ther; 2024 Mar; 30(3):e14664. PubMed ID: 38516781
[TBL] [Abstract][Full Text] [Related]
9. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.
Stermann A; Huebener N; Seidel D; Fest S; Eschenburg G; Stauder M; Schramm A; Eggert A; Lode HN
Cancer Immunol Immunother; 2015 Oct; 64(10):1215-27. PubMed ID: 26076666
[TBL] [Abstract][Full Text] [Related]
10. Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression.
Chittavanich P; Saengwimol D; Roytrakul S; Rojanaporn D; Chaitankar V; Srimongkol A; Anurathapan U; Hongeng S; Kaewkhaw R
Mol Oncol; 2024 Apr; 18(4):918-938. PubMed ID: 37975412
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.
Hansford LM; Thomas WD; Keating JM; Burkhart CA; Peaston AE; Norris MD; Haber M; Armati PJ; Weiss WA; Marshall GM
Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12664-9. PubMed ID: 15314226
[TBL] [Abstract][Full Text] [Related]
12. MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
Zeineldin M; Federico S; Chen X; Fan Y; Xu B; Stewart E; Zhou X; Jeon J; Griffiths L; Nguyen R; Norrie J; Easton J; Mulder H; Yergeau D; Liu Y; Wu J; Van Ryn C; Naranjo A; Hogarty MD; Kamiński MM; Valentine M; Pruett-Miller SM; Pappo A; Zhang J; Clay MR; Bahrami A; Vogel P; Lee S; Shelat A; Sarthy JF; Meers MP; George RE; Mardis ER; Wilson RK; Henikoff S; Downing JR; Dyer MA
Nat Commun; 2020 Feb; 11(1):913. PubMed ID: 32060267
[TBL] [Abstract][Full Text] [Related]
13. The MicroRNA Landscape of MYCN-Amplified Neuroblastoma.
Misiak D; Hagemann S; Bell JL; Busch B; Lederer M; Bley N; Schulte JH; Hüttelmaier S
Front Oncol; 2021; 11():647737. PubMed ID: 34026620
[No Abstract] [Full Text] [Related]
14. High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.
Stauffer JK; Orentas RJ; Lincoln E; Khan T; Salcedo R; Hixon JA; Back TC; Wei JS; Patidar R; Song Y; Hurd L; Tsokos M; Lai EW; Eisenhofer G; Weiss W; Khan J; Wigginton JM
Cancer Invest; 2012 Jun; 30(5):343-63. PubMed ID: 22571338
[TBL] [Abstract][Full Text] [Related]
15. Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma.
Soriano A; Masanas M; Boloix A; Masiá N; París-Coderch L; Piskareva O; Jiménez C; Henrich KO; Roma J; Westermann F; Stallings RL; Sábado C; de Toledo JS; Santamaria A; Gallego S; Segura MF
Cell Mol Life Sci; 2019 Jun; 76(11):2231-2243. PubMed ID: 30770954
[TBL] [Abstract][Full Text] [Related]
16. MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription.
Liu Z; Zhang X; Xu M; Hong JJ; Ciardiello A; Lei H; Shern JF; Thiele CJ
PLoS Biol; 2024 Mar; 22(3):e3002240. PubMed ID: 38547242
[TBL] [Abstract][Full Text] [Related]
17. ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.
Wang L; Tan TK; Durbin AD; Zimmerman MW; Abraham BJ; Tan SH; Ngoc PCT; Weichert-Leahey N; Akahane K; Lawton LN; Rokita JL; Maris JM; Young RA; Look AT; Sanda T
Nat Commun; 2019 Dec; 10(1):5622. PubMed ID: 31819055
[TBL] [Abstract][Full Text] [Related]
18. Unsaturated Fatty Acid Synthesis Is Associated with Worse Survival and Is Differentially Regulated by
Sheeter DA; Garza S; Park HG; Benhamou LE; Badi NR; Espinosa EC; Kothapalli KSD; Brenna JT; Powers JT
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672672
[No Abstract] [Full Text] [Related]
19. When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.
Liu Z; Thiele CJ
Cancer Cell; 2017 Sep; 32(3):273-275. PubMed ID: 28898690
[TBL] [Abstract][Full Text] [Related]
20. Addiction to B-MYB.
Gustafson WC; Weiss WA
Oncotarget; 2010 Aug; 1(4):235-236. PubMed ID: 21304174
[No Abstract] [Full Text] [Related]
[Next] [New Search]